Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Non-Current Assets (2019 - 2025)

Burning Rock Biotech has reported Non-Current Assets over the past 7 years, most recently at $11.5 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 23.79% year-over-year to $11.5 million; the TTM value through Dec 2025 reached $11.5 million, down 23.79%, while the annual FY2025 figure was $11.7 million, 21.46% down from the prior year.
  • Non-Current Assets for Q4 2025 was $11.5 million at Burning Rock Biotech, up from $10.2 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $71.6 million in Q4 2021 and troughed at $10.2 million in Q3 2025.
  • A 5-year average of $35.9 million and a median of $31.5 million in 2023 define the central range for Non-Current Assets.
  • Biggest five-year swings in Non-Current Assets: surged 240.35% in 2021 and later crashed 64.09% in 2025.
  • Year by year, Non-Current Assets stood at $71.6 million in 2021, then crashed by 35.43% to $46.2 million in 2022, then plummeted by 53.15% to $21.7 million in 2023, then crashed by 30.12% to $15.1 million in 2024, then decreased by 23.79% to $11.5 million in 2025.
  • Business Quant data shows Non-Current Assets for BNR at $11.5 million in Q4 2025, $10.2 million in Q3 2025, and $11.7 million in Q2 2025.